Clinical Trial

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

A new partnership between biotech leader Debut and Amazonian expert Natura aims to revolutionize anti-aging skincare with AI-discovered ingredients.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.

John Theurer Cancer Center presents breakthroughs in CAR-T, ADCs, and health equity at ASCO, offering new hope for patients worldwide.

A new global repository by Zifo and the Pistoia Alliance aims to standardize biological data, promising to accelerate drug discovery and fix costly data silos.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

A landmark Novo Nordisk study finds 2 in 5 heart patients have hidden inflammation, a major risk for heart attack and stroke despite standard treatments.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

Studies reveal an AI platform slashes cancer patient hospitalizations by up to 51% and saves millions, heralding a new era of remote oncology care.

A landmark survey shows medical cannabis helps 97% of mental health patients, but experts urge caution, highlighting a divide between patient experience and clinical proof.

Caliway Biopharma advances its fat-loss drug, promising objective, MRI-verified results in a market hungry for safer, more reliable aesthetic options.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.